IQVIA (NYSE:IQV) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus raised their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Evercore ISI upped their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $235.00 in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Trading Down 1.3%

NYSE IQV opened at $238.03 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The firm’s fifty day simple moving average is $227.30 and its 200-day simple moving average is $203.34. The company has a market capitalization of $40.54 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.42 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the company posted $2.84 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Perigon Wealth Management LLC grew its stake in shares of IQVIA by 4.0% in the fourth quarter. Perigon Wealth Management LLC now owns 2,807 shares of the medical research company’s stock worth $633,000 after acquiring an additional 107 shares during the last quarter. Aberdeen Group plc grew its position in IQVIA by 39.6% in the 4th quarter. Aberdeen Group plc now owns 192,696 shares of the medical research company’s stock worth $43,436,000 after purchasing an additional 54,703 shares during the last quarter. Earned Wealth Advisors LLC increased its holdings in shares of IQVIA by 19.0% during the 4th quarter. Earned Wealth Advisors LLC now owns 1,572 shares of the medical research company’s stock worth $354,000 after purchasing an additional 251 shares during the period. HF Advisory Group LLC raised its position in shares of IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after buying an additional 146,444 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of IQVIA by 24.3% in the fourth quarter. Blue Trust Inc. now owns 537 shares of the medical research company’s stock valued at $121,000 after buying an additional 105 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.